Merck says some patents for its top-selling cancer drug, Keytruda, may be extended through 2029.

For full-year 2025, Merck reported worldwide sales of $65B, up 1% Y/Y, or 2% excluding FX, while adjusted EPS totaled $8.98. Analysts had projected EPS of $8.94 for 2025 on revenue of $64.78B.

Merck (MRK) ’s stock surged by 41% in the last six months, driven not only by a modest revenue increase but also by a ...

Merck’s stock falls as the full-year revenue and profit outlooks were below expectations.

Merck & Co. reports Q4 2025 earnings on Tuesday, Feb. 3, 2026, before market open. Wall Street expects earnings of $2.01 per ...

In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and J&J (NYSE: JNJ) primarily due to ...

Merck tops Q4 EPS and sales estimates as Keytruda drives growth, but shares fall in pre-market trading as 2026 guidance ...

PayPal ( PYPL) stock tumbled 16.9% before the opening bell after the fintech issued disappointing guidance, delivered weaker-than-expected Q4 earnings and revenue, and replaced its CEO. The board ...

The latest market snapshot at Thursday morning reveals Merck & Co shares up by 1.21%, trading at $108.19. About Merck & Co. Merck makes pharmaceutical products to treat several co ...

Merck will report its earnings on Tuesday, offering insights into how its agreement to lower the price of its diabetes drug ...

Merck & Co. has underperformed the broader market over the past year, but analysts are moderately optimistic about the ...